Citation

Bag-Ozbek A, Hui-Yuen JS. Ther. Clin. Risk Manag. 2021; 17: 39-54.

Copyright

(Copyright © 2021, Dove Press)

DOI

10.2147/TCRM.S252592

PMID

unavailable

Abstract

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab, obinutuzumab, obexelimab, epratuzumab, daratumumab), B-cell survival factors (belimumab, tabalumab, atacicept, blisibimod), or B-cell intracellular functions (ibrutinib, fenebrutinib, proteasome inhibitors), for the management of SLE. It focuses on ongoing clinical trials and real-world post-marketing use, where available, including their safety profiles, and concludes with our recommendations for B-cell-centric approaches to the management of SLE. © 2021 Bag-Ozbek and Hui-Yuen.

Language: en

Keywords

human; Review; Treatment; insomnia; suicidal ideation; depression; anxiety; drug use; suicide attempt; mental disease; drug intoxication; neutropenia; thrombocytopenia; signal transduction; nonhuman; drug safety; sepsis; drug fatality; drug efficacy; fever; proteinuria; systemic lupus erythematosus; infection; Systemic lupus erythematosus; multiple sclerosis; cellulitis; pneumonia; unspecified side effect; polyneuropathy; intestine perforation; upper respiratory tract infection; bortezomib; multiple myeloma; sensory neuropathy; lupus erythematosus nephritis; progressive multifocal leukoencephalopathy; randomized controlled trial (topic); chronic lymphatic leukemia; thrombocytopenic purpura; rituximab; lung hemorrhage; brain vasculitis; B cell activating factor; belimumab; phase 2 clinical trial (topic); phase 3 clinical trial (topic); atacicept; Belimumab; tabalumab; B lymphocyte; ocrelizumab; Rituximab; double stranded DNA antibody; infusion related reaction; phase 1 clinical trial (topic); ibrutinib; autoimmune hemolytic anemia; blisibimod; Bruton tyrosine kinase; daratumumab; epratuzumab; Epratuzumab; fenebrutinib; immunoglobulin deficiency; lymphatic system malignancy; Novel B-cell therapies; obexelimab; obinutuzumab; ofatumumab